buoy kra data
winner read-across kra data
increas excit target solidifi clinic rational
earli pr patient nsclc sd patient
pr set high bar especi nsclc earli dataset
sever featur preclin dataset may hint differenti
may longer half-lif preclin project point compar
differ solubl may lead differ tissu penetr
measur volum distribut deeper respons mous model
look forward data oct increas pt
consid star base strong efficaci signal
lung cancer nsclc patient heavili pretreat includ
mani fail prior therapi checkpoint inhibitor achiev
diseas control includ partial respons stabl diseas
achiev sd patient pr
kra inhibit via show clean safeti profil dlt
grade treatment-emerg patient anemia
diarrhea diarrhea resolv patient anemia grade anemia
bl target kra bind locat believ
reason expect similar side-effect profil
sever featur preclin dataset may hint differenti
may longer half-lif preclin project point
compar exposur remain
perk assay accord compani provid
suffici durat kra inhibit
addit preclin differ includ differ solubl may lead
differ tissu penetr measur volum distribut
fold differ deeper respons mous model remain
seen differ translat clinic differ especi
small hint combin strategi could lead
differenti
clinic data could present fall dose start
escal subsequ dose level trial could
expand becom registr trial view moa kra inhibit
partli valid data increas po rais
pt prior
year price histori
mirati clinical-stag
genet defin tumor
analyst certif import disclosur see disclosur
model launch nsclc sitravatinib nivolumab
model potenti kra launch
estim sell price experiment product
low mirati gain fda approv indic
model market penetr rapid
estim would signific upsid estim
anticip mirati commerci development-stag
drug sitravatinib nsclc renal cell kra inhibitor
believ candid
potenti well differenti product profil especi
target kra difficult-to-drug
initi sitravatinib nsclc studi refractori
orr interim data sitravatinib nsclc studi
os data sitravatinib nsclc studi
acknowledg possibl signific downsid
estim due inher risk drug develop
worst case mirati stock could littl valu
valu use dcf valuat methodolog price target base dcf valuat wacc residu
growth rate base patent expir
biggest risk price target possibl product candid gain fda approv therefor becom
commerci product gain approv risk obtain includ potenti inabl get favor price patient behavior
physician adopt product patent protect structur chang healthcar market
probabl success
probabl success
probabl success
probabl success
collabor revenu mileston
good
research devleop
adjust research develop non-gaap
share-bas compens
total share-bas compenst
gener administr
adjust sell gener administr non-gaap
share-bas compens sg
total share-bas compenst
total share-bas compens exclud non-gaap
total non-oper income/ expens
earn tax loss
